The tools, originally utilized during the COVID-19 pandemic, are now intended to work alongside FDA’s standard procedures.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com
On Sept. 21, 2023, FDA released a new guidance on how the agency plans to utilize alternative tools to remotely evaluate drug manufacturing facilities identified in a marketing application. The application may be a new drug application, an abbreviated new drug application, a biologics license application, or a supplement to any of these applications. These tools include requesting records from manufacturers, remote interactive assessments of facilities, and receiving information from foreign regulatory partners. During the COVID-19 pandemic, FDA was able to use alternative tools to evaluate facilities; now, it intends to continue to use those tools when appropriate. This guidance is intended to assist FDA in keeping operational flexibility and bolstering faster availability of new, generic, and biosimilar drugs for patients.
The guidance covers the risk-based use of alternative tools, the considerations for alternative tools, and the effects of using alternative tools. Considerations include remote regulatory assessments, inspections conducted by trusted foreign regulatory partners (including information sharing with said partners, and foreign regulatory inspections with FDA remote participants), and preapproval inspections and prelicense inspections with FDA remote subject matter experts.
Alternative tools are used by tFDA to assist the agency in verifying that manufacturers are following regulations and consistently producing high-quality drugs. FDA may use alternative tools to support oversight and evaluation in advance, in lieu, or in support of an inspection. This guidance is not applicable to other drug inspection programs such as post-approval inspections, follow-up and compliance inspections, surveillance inspections, and bioresearch monitoring inspections.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.